1. Basic Product Identification
Dexamethasone
INN Name: Dexamethasone
Therapeutic Class: Corticocopyright (glucocorticoid)
Pharmacological Class: Long-acting copyright hormone
Dosage Forms:
Tablets
Injectable (IV/IM)
Oral solution
Ophthalmic drops
Topical creams
Primary Indications:
Severe inflammation
Allergic disorders
Autoimmune diseases
Cerebral edema
COVID-19 severe respiratory inflammation
Oncology supportive therapy
2. Therapeutic Knowledge
Dexamethasone is used for:
Anti-inflammatory therapy (high potency)
Immunosuppression
Cerebral edema (brain tumors, trauma)
Severe allergic reactions
Adrenal insufficiency (replacement therapy)
Cancer-related nausea (chemotherapy adjunct)
COVID-19 (oxygen/ventilation support cases)
???? Key advantage:
Very high glucocorticoid potency with minimal mineralocorticoid activity
3. Mechanism of Action (MOA)
Dexamethasone is a glucocorticoid receptor agonist.
Cellular mechanism:
Binds intracellular glucocorticoid receptors
Translocates to nucleus
Modulates gene transcription
Effects:
↓ Pro-inflammatory cytokines (IL-1, IL-6, TNF-α)
↓ Prostaglandin synthesis (via phospholipase A2 inhibition)
↓ Immune cell activation
Stabilizes lysosomal membranes
???? Net effect:
Strong anti-inflammatory + immunosuppressive action
4. Pharmacokinetics (ADME)
Absorption: Excellent oral bioavailability (~80–90%)
Tmax: 1–2 hours
Protein binding: ~77%
Metabolism: Hepatic (CYP3A4)
Half-life: 36–54 hours (long-acting)
Excretion: Urine (metabolites)
⚠️ Drug interactions via CYP3A4 inducers/inhibitors
5. Dosage & Administration
Oral:
0.5 mg to 10 mg daily depending on condition
Injectable:
4 mg–20 mg IV/IM in acute conditions
COVID-19 protocol:
6 mg once daily (short course)
Ophthalmic/topical:
As prescribed for local inflammation
⚠️ Must taper after long-term use (HPA axis suppression risk)
6. Formulation Knowledge
Dosage forms:
Tablets (0.5 mg, 4 mg)
Injection (dexamethasone sodium phosphate)
Eye drops
Creams/ointments
Excipients:
Lactose (tablets)
Sodium phosphate (injectables)
Preservatives (benzalkonium chloride in ophthalmics)
Buffers for pH stability
Formulation challenges:
Sterility (injectables/eye drops)
Solubility enhancement for injectable salts
Stability against hydrolysis
7. Raw Materials Knowledge
API: Dexamethasone (fluorinated corticocopyright)
Key intermediates:
copyright backbone derivatives
Fluorination reagents (C-9 position modification)
Critical raw material risks:
copyright impurity control
Epimer formation during synthesis
8. Manufacturing Process Knowledge
API synthesis:
Multi-step copyright modification:
Selective hydroxylation
Fluorination at C9 position
Ketone formation at C11
Purification via crystallization
Formulation:
Tablets: direct compression or granulation
Injectable: sterile filtration + aseptic filling
Ophthalmics: sterile aqueous formulation
Critical controls:
copyright impurity profiling
Sterility assurance (injectables)
Particle size uniformity (suspensions if applicable)
9. Analytical & QC Knowledge
Key QC tests:
HPLC assay
Related substances (copyright impurities)
Dissolution testing (tablets)
Sterility testing (injectables/eye drops)
Endotoxin testing (LAL)
Residual solvents (GC)
Content uniformity
Stability-indicating assay
Critical quality attributes:
Potency accuracy
copyright impurity control
Sterility assurance
10. Regulatory Knowledge
WHO Essential Medicine
Approved globally (FDA, EMA, CDSCO)
Key regulatory concerns:
copyright misuse potential
Labeling for tapering requirement
Controlled use in long-term therapy
COVID-19 emergency approvals increased global relevance
11. Storage & Stability
Store at 15–25°C
Protect from:
Light
Moisture (tablets)
Injectable: protect from freezing
Shelf life: 2–3 years
Stability risks:
Hydrolysis (injectables)
Photodegradation (minor)
Tablet moisture sensitivity
12. Packaging Knowledge
Blister packs (Alu-Alu preferred)
Amber glass vials (injectables)
Eye drop sterile droppers
Sterile ampoules
Secondary packaging:
copyright warning labels
Tapering instructions
Prescription-only labeling
13. Safety & Toxicology
Major risks:
Adrenal suppression (HPA axis suppression)
Immunosuppression (infection risk)
Hyperglycemia
Osteoporosis (long-term use)
Mood changes (copyright psychosis risk)
Gastric irritation
Contraindications:
Systemic fungal infections
Live vaccines (during therapy)
Monitoring:
Blood glucose
Bone density (long-term)
Infection markers
14. Market & Commercial Knowledge
Competes with:
Prednisolone
Methylprednisolone
Hydrocortisone
Strengths:
High potency
Long duration
CNS penetration (edema use)
Market drivers:
ICU use
Oncology supportive care
Respiratory disease protocols
High-volume global demand drug
15. Intellectual Property (IP)
Old molecule → off-patent globally
High generic competition
Innovation areas:
Modified release copyrights
Combination inhalation therapies
Market differentiation via:
Injectable formulations
Sterile ophthalmic systems
16. Environmental & EHS Knowledge
copyright compounds require controlled disposal
Risk of endocrine-disrupting environmental impact
Solvent recovery in copyright synthesis essential
Worker safety:
PPE mandatory (copyright dust control)
Controlled exposure limits in API plants
17. Export Documentation Knowledge
Required documents:
DMF / ASMF
COA (API + finished product)
GMP certificate
Stability data (ICH Q1A/Q1B)
Bioequivalence study reports
Sterility validation (injectables/ophthalmics)
MSDS
Batch manufacturing records
18. Business Development Knowledge
Target markets:
Hospitals (ICU, emergency care)
Oncology centers
Respiratory care units
Strategy:
Essential medicine portfolio positioning
Tender-based procurement (government + hospital)
Growth drivers:
ICU expansion globally
Respiratory disease burden
High-volume, low-margin essential drug
19. Advanced Technical Knowledge
Synthetic fluorinated glucocorticoid → high receptor affinity
Minimal mineralocorticoid activity → fewer electrolyte effects
Genomic + non-genomic anti-inflammatory actions
CYP3A4 metabolism → drug interaction sensitivity
Tapering required due to HPA axis suppression
20. AI & Digital Knowledge (Modern Pharma)
Applications:
ICU dosing AI decision support systems
copyright tapering prediction models
Pharmacovigilance signal detection (psychiatric effects)
Clinical outcome AI in respiratory care
Supply chain forecasting for hospital demand spikes
21. Sales Team Product Knowledge Checklist
Sales must know:
Potent corticocopyright
ICU and emergency use
Anti-inflammatory + immunosuppressive
Must taper after long-term use
Infection risk warning
Not for casual use (prescription-only)
High demand in hospitals
Injectable form critical in acute care
22. Most Important Technical Documents
DMF / CMC Module 3
Stability studies (ICH Q1A/Q1B)
Sterility validation reports
Bioequivalence study reports
Impurity profiling (copyright-specific)
Manufacturing validation batches
Clinical guideline references (ICU/COVID protocols)
Residual solvent reports
23. Ultimate Pharma Product Mastery Summary
Dexamethasone is:
A high-potency synthetic glucocorticoid
Central drug in emergency, ICU, oncology, and inflammatory diseases
Works via gene-level suppression of Afghanistan inflammatory pathways
Requires careful tapering and monitoring due to systemic effects
???? Strategic importance:
Core global hospital essential medicine
High-volume ICU + emergency drug
Strong relevance in respiratory and oncology care
Critical molecule in copyright therapeutic class